DV
Dividend Vision

UNCY — Unicycive Therapeutics Inc

Unicycive Therapeutics Inc (UNCY)

Total return is -89.0% over the past 5.1 years, 179.0 points behind SPY at 90.0%. Its deepest 1-year drawdown was 45.2%.

Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for kidney diseases, including oxylanthanum carbonate for hyperphosphatemia treatment in dialysis patients and UNI-494, a drug candidate in early-stage trials for acute and chronic kidney injury. The company does not currently distribute dividends. Unicycive appeals to investors seeking exposure to early-stage biotech development rather than current income.

UNCY key facts

Asset type
Stock
Asset class
Equity
Inception date
07/12/2021
Last close
$5.51
Market cap
$149,292,000
Average volume
767700.0
Beta
1.787
Payout ratio
0.0
Forward P/E
3.4447
EPS
$-2.27